- Home
- GTIM vs BLRX Comparison
GTIM vs BLRX Comparison
Compare GTIM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTIM
- BLRX
- Stock Information
- Founded
- GTIM 1987
- BLRX 2003
- Country
- GTIM United States
- BLRX Israel
- Employees
- GTIM N/A
- BLRX N/A
- Industry
- GTIM Restaurants
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GTIM Consumer Discretionary
- BLRX Health Care
- Exchange
- GTIM Nasdaq
- BLRX Nasdaq
- Market Cap
- GTIM 17.1M
- BLRX 17.0M
- IPO Year
- GTIM 1990
- BLRX 2011
- Fundamental
- Price
- GTIM $1.62
- BLRX $4.04
- Analyst Decision
- GTIM
- BLRX Strong Buy
- Analyst Count
- GTIM 0
- BLRX 2
- Target Price
- GTIM N/A
- BLRX $19.00
- AVG Volume (30 Days)
- GTIM 29.6K
- BLRX 33.6K
- Earning Date
- GTIM 08-07-2025
- BLRX 08-14-2025
- Dividend Yield
- GTIM N/A
- BLRX N/A
- EPS Growth
- GTIM 17.03
- BLRX N/A
- EPS
- GTIM 0.12
- BLRX N/A
- Revenue
- GTIM $143,398,000.00
- BLRX $17,251,000.00
- Revenue This Year
- GTIM N/A
- BLRX N/A
- Revenue Next Year
- GTIM N/A
- BLRX N/A
- P/E Ratio
- GTIM $13.74
- BLRX N/A
- Revenue Growth
- GTIM 1.78
- BLRX 1.19
- 52 Week Low
- GTIM $1.34
- BLRX $2.30
- 52 Week High
- GTIM $3.20
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- GTIM 48.83
- BLRX 55.55
- Support Level
- GTIM $1.52
- BLRX $3.42
- Resistance Level
- GTIM $1.69
- BLRX $4.36
- Average True Range (ATR)
- GTIM 0.09
- BLRX 0.26
- MACD
- GTIM -0.01
- BLRX 0.07
- Stochastic Oscillator
- GTIM 31.25
- BLRX 65.96
About GTIM Good Times Restaurants Inc.
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.